Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
ATP Energy Storage and Release01:31

ATP Energy Storage and Release

10.0K
ATP is a highly unstable molecule. Unless quickly used to perform work, ATP spontaneously dissociates into ADP and inorganic phosphate (Pi), and the free energy released during this process is lost as heat. The energy released by ATP hydrolysis is used to perform work inside the cell and depends on a strategy called energy coupling. Cells couple the exergonic reaction of ATP hydrolysis with endergonic reactions, allowing them to proceed.
One example of energy coupling using ATP involves a...
10.0K
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

1.6K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.6K
Hydrolysis of ATP01:08

Hydrolysis of ATP

72.3K
The bonds of adenosine triphosphate (ATP) can be broken through the addition of water, releasing one or two phosphate groups in an exergonic process called hydrolysis. This reaction liberates the energy in the bonds for use in the cell—for instance, to synthesize proteins from amino acids.
If one phosphate group is removed, a molecule of ADP—adenosine diphosphate—remains, along with inorganic phosphate. ADP can be further hydrolyzed to AMP—adenosine...
72.3K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
ATP Driven Pumps I: An Overview01:27

ATP Driven Pumps I: An Overview

8.0K
ATP-driven pumps, also known as transport ATPases, are integral membrane proteins. They have binding sites for ATP located on the membrane's cytosolic side and the ion-conducting domain in the transmembrane region. These pumps use the free energy released from ATP hydrolysis to move the solutes across cell membranes against an electrochemical gradient.
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of prognostic outcomes in vitrectomy for myopic foveoschisis with foveal detachment: air tamponade versus no-air tamponade.

International journal of retina and vitreous·2026
Same author

Gut-Liver Axis Mechanisms Underlying Spontaneous Reversal of Liver Fibrosis: A Gut Microbiota-Metabolomics Analysis.

Metabolites·2026
Same author

Non-invasive monitoring of hyperuricemia via a flexible SERS sensor with ultrahigh sensitivity.

Mikrochimica acta·2026
Same author

EGCG inactivates tumor necrosis factor-alpha (TNFα) by inducing its higher-order assembly.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Cas9-PALB2 fusion protein enhances CRISPR/Cas9 mediated gene knock-in efficiency.

Journal of bioscience and bioengineering·2026
Same author

Implantable core-shell microneedles enable biphasic release of insulin for immediate and sustained glycemic regulation.

International journal of biological macromolecules·2026

Related Experiment Video

Updated: Apr 23, 2026

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
03:49

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

1.3K

Adenosine amine congener as a cochlear rescue agent.

Srdjan M Vlajkovic1, Hao Chang2, Song Yee Paek2

  • 1Department of Physiology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand ; Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.

Biomed Research International
|September 23, 2014
PubMed
Summary

Adenosine amine congener (ADAC) effectively rescues noise-induced hearing loss in rats when administered within 24 hours post-exposure. This study highlights ADAC

More Related Videos

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

8.8K
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

18.9K

Related Experiment Videos

Last Updated: Apr 23, 2026

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation
03:49

Author Spotlight: Optimizing EAS with Long Electrodes for Enhanced Cochlear Coverage and Hearing Preservation

Published on: October 11, 2024

1.3K
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

8.8K
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

18.9K

Area of Science:

  • Oto-neurology
  • Pharmacology
  • Auditory Neuroscience

Background:

  • Noise-induced hearing loss (NIHL) is a significant health concern.
  • Adenosine amine congener (ADAC), an A1 adenosine receptor agonist, has shown potential in mitigating cochlear injury.
  • Previous studies indicated ADAC's protective effects against noise- and cisplatin-induced cochlear damage.

Purpose of the Study:

  • To investigate the dose-dependent protective effects of ADAC against noise-induced cochlear injury in a rat model.
  • To determine the optimal time window for ADAC administration following noise exposure.
  • To assess the pharmacokinetic profile of ADAC after systemic administration.

Main Methods:

  • Wistar rats were exposed to traumatic noise (110 dB SPL, 2 hours).
  • ADAC (25-300 μg/kg) was administered intraperitoneally at various intervals (6-72 hours) post-noise exposure.
  • Hearing sensitivity was evaluated using auditory brainstem responses (ABR) before and 12 days after noise exposure.
  • Pharmacokinetic studies analyzed ADAC plasma concentrations following intravenous administration.

Main Results:

  • ADAC demonstrated significant, dose-dependent protection against NIHL, with optimal efficacy observed within 24 hours post-exposure.
  • Doses greater than 50 μg/kg provided up to 21 dB of hearing protection across tested frequencies.
  • Pharmacokinetic analysis revealed a short plasma half-life (5 minutes) for ADAC without detectable degradation products.

Conclusions:

  • ADAC effectively mitigates noise-induced hearing loss in a dose- and time-dependent manner in a rat model.
  • The findings support ADAC's potential as a therapeutic agent for NIHL.
  • Further research is necessary to evaluate ADAC's clinical applicability in otological treatments.